NCT01232439

A Study of Brain Receptor Occupancy in Healthy Subjects

Assessment of Brain Kappa Opioid Receptor Occupancy After Single Oral Doses of LY2456302 as Measured by PET With Radioligand LY2879788 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.

Conditions

• Alcohol Dependence

Interventions

Type	Name	Description
DRUG	opioid receptor kappa antagonist	Starting dose of 2 mg, administered orally, once. The potential dose range for this study is 0.2 mg to 30 mg

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2010-11-02
• Last updated: 2011-05-09

Locations

1 site across 1 country: United States